Table 1.
Baseline and final (36-month) clinical characteristics in the T&E and mT&E groups
| Baseline | 36 month follow-up | |||||
| T&E group (n=135 eyes) | mT&E group (n=119 eyes) | P value* | T&E group (n=135 eyes) | mT&E group (n=119 eyes) | P value* | |
| LogMAR BCVA | 0.69±0.63 | 0.78±0.69 | 0.28 | 0.72±0.70 | 0.74±0.76 | 0.83 |
| BCVA | ||||||
| 20/200 or worse | 27 (22.7) | 32 (23.7) | 0.36 | 32 (26.9) | 33 (24.4) | 0.67 |
| >20/200 to <20/40 | 47 (39.5) | 68 (50.4) | 0.10 | 35 (29.4) | 52 (38.5) | 0.15 |
| 20/40 or better | 45 (37.8) | 35 (25.9) | 0.04 | 52 (43.7) | 50 (37.1) | 0.31 |
| ETDRS letter ≥45 | 103 (86.6) | 83 (61.5) | <0.001 | 99 (83.2) | 83 (61.5) | <0.001 |
| CPT, microns | 408.7±183 | 370.8±192.7 | 1.00 | 326.7±204 | 273.3±116.5 | 0.05 |
| CST, microns | 414.7±145.7 | 390.4±119.7 | 1.00 | 349.1±166 | 307.5± 106.9 |
0.04 |
| IRF | 64 (47.4) | 53 (44.5) | 0.71 | 44 (32.6) | 37 (31.1) | 0.89 |
| SRF | 80 (59.3) | 72 (60.5) | 0.90 | 38 (28.2) | 26 (21.8) | 0.31 |
| PED | 53 (39.3) | 80 (67.2) | <0.001 | 47 (34.8) | 72 (60.5) | <0.001 |
| Scar | 8 (5.9) | 6 (5.0) | 0.79 | 52 (38.5) | 55 (46.2) | 0.25 |
| Atrophy | 6 (4.4) | 8 (6.7) | 0.58 | 52 (38.5) | 53 (44.5) | 0.37 |
Data are presented as the mean±SD or n (%).
*Calculated using Student’s t-test or Fisher’s exact test.
BCVA, best-corrected visual acuity; CPT, central point thickness; CST, central subfield thickness; ETDRS, Early Treatment for Diabetic Retinopathy Study; IRF, intraretinal fluid; mT&E, modified treat-and-extend; PED, pigment epithelial detachment; SRF, subretinal fluid; T&E, treat-and-extend.